|
|
News Breaks
|
November 4, 2009
|
| 07:04 EDT |  | ISPH |
| theflyonthewall.com: | Inspire completes patient enrollment in threee late-stage trials | | Inspire Pharmaceuticals announced patient enrollment is complete in three of its late-stage clinical trials. Inspire announced today that TIGER-2, the company’s second Phase 3 pivotal clinical trial with denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis, has completed patient enrollment. Inspire also announced today that patient enrollment is complete in its Phase 3 clinical trial with PROLACRIA, the proposed U.S. tradename for diquafosol tetrasodium ophthalmic solution 2%, for the treatment of dry eye disease. :theflyonthewall.com |
|
|
News For ISPH From The Last 14 Days Check below for free stories on ISPH the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
